What is ENDRA Life Sciences Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ENDRA Life Sciences's annualized net income for the quarter that ended in Mar. 2024 was $-11.10 Mil. ENDRA Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $4.68 Mil. Therefore, ENDRA Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -237.34%.
The historical rank and industry rank for ENDRA Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NDRA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -533.1 Med: -196.58 Max: -125.12
Current: -190.39
During the past 10 years, ENDRA Life Sciences's highest Return-on-Tangible-Equity was -125.12%. The lowest was -533.10%. And the median was -196.58%.
NDRA's Return-on-Tangible-Equity is ranked worse than 89.8% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.885
vs NDRA: -190.39
ENDRA Life Sciences Return-on-Tangible-Equity Historical Data
The historical data trend for ENDRA Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ENDRA Life Sciences Return-on-Tangible-Equity Chart
Competitive Comparison of ENDRA Life Sciences's Return-on-Tangible-Equity
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Return-on-Tangible-Equity falls into.
ENDRA Life Sciences Return-on-Tangible-Equity Calculation
ENDRA Life Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
ENDRA Life Sciences (NAS:NDRA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ENDRA Life Sciences Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your 